Mejores médicos.

Las VILLAPEPAS
de FÁRMACOS
Que se trabajan
en los ensayos
clínicos contra
El COVID-19

Dr. Manolo Briceño Alvarado

@mbaclinicsurgery
@mbacardiovasculares
 Mejores médicos.

Respuesta inmune al SARS-CoV-2 y sepsis viral

COVID-19 y coagulación anormal

PROPUESTA FISIOPATO ACTUAL(HIPÓTESIS)

Hui Li MD, Liang Liu MD, Dingyu Zhang MD, y col. SARS-
CoV-2 and viral sepsis: observations and hypotheses.
2020. LANCET; (en prensa)

@mbaclinicsurgery

PEPAS FISIOPATO - CLÍNICA @mbacardiovasculares

 Mejores médicos.
HOUSE VEDETE
H
O
NO SÍNTOMAS U
LEVE
S
SIN FR CON FR
E
MOD SIN FR CON FR V
E
SEVERO
D
CRÍTICO E
TTE

ETAPA DE ALTA ETAPA DE INICIO DE ETAPA

ETAPA SARS
REPLICACIÓN SARS E TROMBOFÍLICA
HIPERCOAGULABILIDAD
SEVERO Y CID
VIRAL Y AUTOINMUNE
A

A
@mbaclinicsurgery
I
PEPAS CLÍNICA-TERAPÉUTICA @mbacardiovasculares
 Mejores médicos.
USO PARA COVID-19 SIGUE SIENDO DE INVESTIGACIÓN REMDESIVIR>

HIDROXICLOROQUINA / CLOROQUINA >

AZITROMICINA E
HIDROXICLOROQUINA
Inhibidores de la vía de IL-6 :
TOCILIZUMAB:

Lopinavir-ritonavir:

Favipiravir: inh ARN POLIMERASA

Interferón beta:

Plasma convaleciente
ClinicalTrials.gov @mbaclinicsurgery
PEPAS TERAPÉUTICA – ENSAYOS CLÍNICOS @mbacardiovasculares
Mejores médicos.
 Mejores médicos.

1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.
5. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473.
6. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269.
7. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9.
8. Gilead. Remdesivir compassionate use application. https://rdvcu.gilead.com/ (Accessed on March 20, 2020).
9. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020.
10. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020.
11. Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001; 19:420.
12. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect
Dis 2020.
13. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydrochlroquine in patients with COVID-19: Results of a randomized trial. Unpublished. https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.
14. Tang w, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. Unpublished. https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1.full.pdf
15. Borba M, Val F, Sampaio S, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection:
Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). Unpublished. https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2 (Accessed on April 16, 2020).
16. US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. https://bibvirtual.upch.edu.pe:2178/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-
ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.
17. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606.
18. Groneberg DA, Poutanen SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5:147.
19. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
20. WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-
(ncov)-infection-is-suspected
21. Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020.
22. IDSA and HIVMA. COVID-19: Special Considerations for People Living with HIV. April 4, 2020. https://www.idsociety.org/globalassets/covid-19-special-consideratio
23. Alhazzani W, Moller MH, Arabi YM, y col. Campaña de sepsis sobreviviente: pautas sobre el manejo de adultos críticos con enfermedad por coronavirus 2019 (COVI-19). Cuidados Intensivos Med 2020; (en prensa).
24. Huang C, Wang Y, Li X y col. Características clínicas de pacientes infectados con el nuevo coronavirus 2019 en Wuhan, China. Lancet 2020; 395: 497.

@mbaclinicsurgery
@mbacardiovasculares
Mejores médicos.

DESCARGA GRATUITA DEL LIBRO VILLAPEPAS

COVID-19:
www.villamedicgroup.com
Recibe los UPDATE semanales 

@mbaclinicsurgery
@mbacardiovasculares